Clinical trial
First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)
NCT02464436 is registered in ClinicalTrials.gov with ReNeuron Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)
- Lead sponsor
- ReNeuron Limited
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- December 31, 2015
- Completion date
- December 31, 2023
- Enrollment
- 29 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.